Linked Data API

Show Search Form

Search Results

1128068
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-22
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Dementia more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether they plan to publish a national dementia strategy for beyond 2020; and if so, when. more like this
star this property tabling member printed
Baroness Crawley more like this
star this property uin HL15917 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-06more like thismore than 2019-06-06
star this property answer text <p>We expect to publish a new dementia strategy for England for the period 2020 to 2025 early next year.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-06-06T15:50:32.963Zmore like thismore than 2019-06-06T15:50:32.963Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3386
unstar this property label Biography information for Baroness Crawley more like this
1128069
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-22
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Dementia more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what progress they have made towards meeting the aims of the Prime Minister’s challenge on dementia. more like this
star this property tabling member printed
Baroness Crawley more like this
star this property uin HL15918 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-06more like thismore than 2019-06-06
star this property answer text <p>We have committed to implement fully the Government’s <em>Challenge on Dementia 2020</em> strategy to make this country the best place in the world to live with dementia.</p><p> </p><p>Our recent review of progress tells us we are largely on track to meet our commitments to improve the lives of those living with dementia, their families and carers. The<em> Dementia 2020 Challenge: 2018 Review</em> <em>Phase 1</em> report is attached.</p><p> </p><p>Examples of progress we have made so far with our delivery partners include more than two thirds of people with dementia receiving a diagnosis, over 2.8 million people becoming Dementia Friends and 365 areas in England committing to being Dementia Friendly Communities. In the £250 million Dementia Discovery Fund we have the largest venture fund in the world aimed at discovering and developing novel pre-clinical therapies for dementia.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-06-06T15:47:49.24Zmore like thismore than 2019-06-06T15:47:49.24Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name Dementia 2020 Challenge 2018 Review Phase 1.pdf more like this
star this property title Dementia 2020 Challenge 2018 Review Phase 1 more like this
star this property tabling member
3386
unstar this property label Biography information for Baroness Crawley more like this
1127421
star this property registered interest false more like this
star this property date less than 2019-05-20more like thismore than 2019-05-20
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Bacterial Diseases more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 14 May (HL15384), what assessment they have made of the number of people, with or without resistant blood stream infections, who have Carbapenem resistant E. coli-like bacteria present in their bodies; and what (1) proposed, and (2) current, initiatives there are to control the transmission of such bacteria. more like this
star this property tabling member printed
Baroness Gardner of Parkes more like this
star this property uin HL15832 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-04more like thismore than 2019-06-04
star this property answer text <p>The 2018 English surveillance programme for antimicrobial utilisation and resistance report contains information on carbapenem-resistant Escherichia coli (E. coli) causing bloodstream infections in England. In 2017 there were 18 cases. The number of people with other infections and carriage of E. coli resistant to carbapenems is harder to ascertain as surveillance is not as uniform.</p><p>Public Health England (PHE) publishes guidance on the prevention and control of carbapenemase-producing Enterobacteriaceae (including E. coli); guidance is available for both acute and non-acute settings, copies of the <em>Toolkit for managing carbapenemase-producing Enterobacteriaceae in non-acute and community settings</em> and <em>Acute trust toolkit for the early detection, management and control of carbapenemase-producing Enterobacteriaceae</em> are attached. PHE is supporting actions outlined in the United Kingdom’s Tackling Antimicrobial Resistance National Action Plan that aim to prevent and control the transmission of carbapenem-resistant bacteria, which includes reducing the number of specific drug-resistant infections in people by 10% by 2025; reducing UK antimicrobial use in humans by 15% by 2024; and adding carbapenem-resistant Gram-negative infections to the list of notifiable diseases in existing laboratory reporting systems.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name Acute_trust_toolkit_for_the_early_detection.pdf more like this
star this property title Acute trust toolkit more like this
2
star this property file name CPE-Non-AcuteToolkit_CORE.pdf more like this
star this property title CPE Non Acute toolkit more like this
star this property question first answered
less than 2019-06-04T13:45:10.523Zmore like thismore than 2019-06-04T13:45:10.523Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3596
unstar this property label Biography information for Baroness Gardner of Parkes more like this
1126307
star this property registered interest false more like this
star this property date less than 2019-05-13more like thismore than 2019-05-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Civil Proceedings more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how much money the NHS spent as part of legal settlements in each year from 2009 to 2018; and how much of each year's spend relates to legal fees. more like this
star this property tabling member printed
Baroness Hodgson of Abinger more like this
star this property uin HL15667 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-24more like thismore than 2019-05-24
star this property answer text <p>NHS Resolution has provided the following information:</p><p>NHS Resolution has provided tables which cover:</p><p>- total expenditure for NHS Resolution Clinical Negligence Schemes and NHS Resolution non-clinical negligence schemes from 2009 to 2018;</p><p>- the total legal costs per financial year; and</p><p>- the draft budget for legal fees/damages 2019 for NHS Resolution Clinical Negligence Schemes and NHS Resolution non-clinical negligence schemes.</p><p>The data is attached due to the size of the data.</p><p>National Health Service spend on legal fees for matters other than clinical/non-clinical negligence settlements since 2009 has been interpreted as spend relating to NHS providers and commissioners.</p><p>This includes NHS trusts, NHS foundation trusts and NHS England and clinical commissioning groups. NHS spend on legal fees for non-negligence matters is shown in the following table.</p><table><tbody><tr><td><p>Year</p></td><td><p>Total legal fees (£000s)</p></td></tr><tr><td><p>2013-14</p></td><td><p>110,747</p></td></tr><tr><td><p>2014-15</p></td><td><p>171,806</p></td></tr><tr><td><p>2015-16</p></td><td><p>162,273</p></td></tr><tr><td><p>2016-17</p></td><td><p>172,135</p></td></tr><tr><td><p>2017-18</p></td><td><p>160,140</p></td></tr></tbody></table><p>Prior to 2013-14, expenditure on legal fees was not separately classified by primary care trusts and strategic health authorities who both carried out NHS commissioning and NHS trusts. Therefore, comparable information pre 2013-14 is unavailable.</p><p>There is no specific category of expenditure that isolates spend relating to legal settlements in the NHS.</p><p>We have interpreted the request for data for the amounts set aside in 2019 as the value of said provisions as at the end of the financial year, 31 March 2019. This data is still subject to audit and will not be available until after publication of the Annual Report and Accounts in July 2019.</p><p>The budget totals for legal fees relating to NHS spend in 2019 is not available.</p><p> </p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15668 more like this
star this property question first answered
less than 2019-05-24T11:47:45.193Zmore like thismore than 2019-05-24T11:47:45.193Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name HL15667 & HL15668 Data.docx more like this
star this property title HL15667_HL15668_data more like this
star this property tabling member
4301
unstar this property label Biography information for Baroness Hodgson of Abinger more like this
1126308
star this property registered interest false more like this
star this property date less than 2019-05-13more like thismore than 2019-05-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Civil Proceedings more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how much money the NHS has set aside for potential legal settlements in 2019; and how much they have budgeted for legal fees. more like this
star this property tabling member printed
Baroness Hodgson of Abinger more like this
star this property uin HL15668 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-24more like thismore than 2019-05-24
star this property answer text <p>NHS Resolution has provided the following information:</p><p>NHS Resolution has provided tables which cover:</p><p>- total expenditure for NHS Resolution Clinical Negligence Schemes and NHS Resolution non-clinical negligence schemes from 2009 to 2018;</p><p>- the total legal costs per financial year; and</p><p>- the draft budget for legal fees/damages 2019 for NHS Resolution Clinical Negligence Schemes and NHS Resolution non-clinical negligence schemes.</p><p>The data is attached due to the size of the data.</p><p>National Health Service spend on legal fees for matters other than clinical/non-clinical negligence settlements since 2009 has been interpreted as spend relating to NHS providers and commissioners.</p><p>This includes NHS trusts, NHS foundation trusts and NHS England and clinical commissioning groups. NHS spend on legal fees for non-negligence matters is shown in the following table.</p><table><tbody><tr><td><p>Year</p></td><td><p>Total legal fees (£000s)</p></td></tr><tr><td><p>2013-14</p></td><td><p>110,747</p></td></tr><tr><td><p>2014-15</p></td><td><p>171,806</p></td></tr><tr><td><p>2015-16</p></td><td><p>162,273</p></td></tr><tr><td><p>2016-17</p></td><td><p>172,135</p></td></tr><tr><td><p>2017-18</p></td><td><p>160,140</p></td></tr></tbody></table><p>Prior to 2013-14, expenditure on legal fees was not separately classified by primary care trusts and strategic health authorities who both carried out NHS commissioning and NHS trusts. Therefore, comparable information pre 2013-14 is unavailable.</p><p>There is no specific category of expenditure that isolates spend relating to legal settlements in the NHS.</p><p>We have interpreted the request for data for the amounts set aside in 2019 as the value of said provisions as at the end of the financial year, 31 March 2019. This data is still subject to audit and will not be available until after publication of the Annual Report and Accounts in July 2019.</p><p>The budget totals for legal fees relating to NHS spend in 2019 is not available.</p><p> </p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15667 more like this
star this property question first answered
less than 2019-05-24T11:47:45.257Zmore like thismore than 2019-05-24T11:47:45.257Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name HL15667 & HL15668 Data.docx more like this
star this property title HL15667_HL15668_data more like this
star this property tabling member
4301
unstar this property label Biography information for Baroness Hodgson of Abinger more like this
1125504
star this property registered interest false more like this
star this property date less than 2019-05-08more like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Pneumococcal Diseases: Vaccination more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15599 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
star this property answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15600 more like this
star this property question first answered
less than 2019-05-22T14:50:14.54Zmore like thismore than 2019-05-22T14:50:14.54Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf more like this
star this property title JCVI Minute 2015 more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
1125505
star this property registered interest false more like this
star this property date less than 2019-05-08more like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Pneumococcal Diseases: Vaccination more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15600 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
star this property answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15599 more like this
star this property question first answered
less than 2019-05-22T14:50:14.483Zmore like thismore than 2019-05-22T14:50:14.483Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf more like this
star this property title JCVI Minute 2015 more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
1125506
star this property registered interest false more like this
star this property date less than 2019-05-08more like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading HIV Infection: Vaccination more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what steps they are taking to improve vaccination coverage for people living with HIV. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15601 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
star this property answer text <p>Public Health England, in partnership with NHS England and the Department, is taking steps to improve vaccination coverage in England, including for people living with HIV.</p><p>These steps include initiatives to improve access to the immunisation programme; communication with the public; data to identify underserved individuals and populations; and training for healthcare professionals, changes to vaccination eligibility criteria; launching disease elimination strategies; running targeted social media campaigns; providing information leaflets in multiple languages and running e-learning programme for healthcare practitioners.</p><p>Certain vaccines are delivered through sexual health services that particularly benefit people living with HIV. This includes vaccines for hepatitis A, hepatitis B and human papillomavirus. People living with HIV are in the influenza risk groups and are invited for the flu vaccine on an annual basis.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-05-22T14:50:46.107Zmore like thismore than 2019-05-22T14:50:46.107Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
1124901
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Nusinersen more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what discussions they have had with (1) NICE, (2) NHS England, and (3) Biogen, on a Managed Access Agreement for Spinal Muscular Atrophy treatment, Spinraza. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15576 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15577 more like this
star this property question first answered
less than 2019-05-17T11:07:46.62Zmore like thismore than 2019-05-17T11:07:46.62Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
unstar this property label Biography information for Baroness Thomas of Winchester more like this
1124902
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government when they estimate that NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15577 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15576 more like this
star this property question first answered
less than 2019-05-17T11:07:46.673Zmore like thismore than 2019-05-17T11:07:46.673Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
unstar this property label Biography information for Baroness Thomas of Winchester more like this